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Case Report
Ewing’s Sarcoma/PNET of kidney in 13 year old girl

Quratulain Badar,1 Nasir Ali,2 Nadeem Abbasi,3 Shamvil Ashraf,4 Farrok Karsan,5 Raheel Hashmi6
Department of Radiation Oncology the Aga Khan University Hospital,1-3,5,6 Children Cancer Hospital,4 Karachi, Pakistan.

Abstract

Ewing's sarcoma is the second most common primary
tumour of bone in childhood. Less frequently it occurs in soft
tissues. Ewing's sarcoma/primitive neuroectodermal tumour
(ES/PNET) is an extra ordinarily rare primary tumour in the
kidney.1 Only very few cases of primary renal Ewing's sarcoma
have been reported in the literature to date.2 We present a case
of primary right renal Ewing's sarcoma in a 13 year old girl
who was diagnosed as a case of stage IV ES/PNET of kidney
with metastases to lung and liver. Right nephrectomy was done
followed by adjuvant radiotherapy and chemotherapy with
complete response to local and distant area.

Introduction

Ewing's sarcoma is the second most common tumour
of bone in childhood. Less frequently it occurs in soft tissues.
In the European Intergroup Cooperative Ewing's sarcoma
study (EICESS) the median age was 14 years. In the EICSS
24.7% of lesions presented in the pelvis, 16.4% in the femur,
16.7% below the knee, 12.1% in the ribs, 8.0% in the spine
and 4.8% in the humerus.3

Ewing's family of tumour present both as osseous and
extra osseous variants as well as in primitive neuroectodermal
tumours (PNET'S) of bone and soft tissue, peripheral
primitive neuroectodermal tumour, Askin tumour and some
central nervous system tumours.2 Primary Ewing's sarcoma
occurring in the kidney is a rare neoplastic disease of high
malignant potential with a tendency towards early metastases.
Approximately 20% of patients present with metastatic
disease. Effective local as well as systemic therapies are
necessary to cure this highly virulent disease.3 The
presentation and prognosis of the disease in this case was
almost similar to that of ES of bone.
We report a case of a 13-year-old girl who was
diagnosed to have Ewing's sarcoma of kidney with lung and
liver metastases.

Case Report

A 13 years young girl presented with right sided
abdominal pain for one month and haematuria for 2 days. IVP
was done which showed a non functioning right kidney. CT scan
of abdomen and pelvis showed a large infiltrating mass
measuring 6.0 x 9.0 cm occupying the central portion of the right
kidney. The tumour was located entirely within the Gerota's
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Figure: Preoperative CT image.

fascia with no evidence of fascial breach at any level. There was
evidence of peri renal lymphadenopathy. There was focus of non
enhancing lesion in segment 4 of the liver measuring 1.0 x 1.5
cm. Multiple nodules were present in the lung bases bilaterally.
Ultrasound guided Biopsy of right renal mass showed possibility
of ES/PNET. She underwent right radical nephrectomy and the
histopathology was consistent with a tumour with rounded blue
cell and focally tumour was disrupting the renal capsule and
extending into the peri renal fat. Hilum showed infiltration of
tumour around the major blood vessels. The sections were
submitted to a panel of immunohistochemical studies. PAS stain
showed focal glycogen in tumour cells. Immunohistochemical
studies showed strong positivity to Vimentin, MIC-2 and S-100
and focal positivity to EMA, Cytokeratin AE1/AE3 and
Synaptophysin. Cytokeratin 7, LCA and Desmin were negative.
On the basis of these findings diagnosis of Ewing's
sarcoma/PNET of Kidney was made.

After confirmation of the diagnosis she received 6
cycles of CVD+IVE (3 cycles of cyclophosphamide,
vincristine, doxorubicin and 3 cycles of vincristine, Etoposide
and ifosphamide). This was followed by radiotherapy to
tumour bed 50 Gy and later by 4 more cycles of chemotherapy
with the same regime. The duration of chemotherapy was 11
months. CT scan of chest abdomen and pelvis done after 6
cycles of chemotherapy showed complete response in local as
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well as in distant areas and it was showing no evidence of
disease at local site as well as in lungs. Repeat CT scan after
completion of radiotherapy was also reported to show no
evidence of disease. She was advised to have close follow up,
unfortunately lung metastases reappeared 21 months after
completion of therapy. At relapse of disease she was offered
palliative radiotherapy to lungs for control of symptoms.
There was slight improvement in her symptoms but expired 5
months after the discovery of recurrent lung mets.

Discussion

Ewing's sarcoma (ES) initially was believed to be of
perivascular endothelial origin. The Ewing's sarcoma family
of tumours (EFT) includes ES of bone (ESB), extra osseous
ES (EES), peripheral primitive neuroectodermal tumour of
bone (pPNET), and malignant small-cell tumour of the
thoracopulmonary region, or Askin's tumour, all of which are
now known to be neoplasm's of neuroectodermal origin.
Because the behaviour, prognosis, and treatment appear to be
similar for all subsets of EFT, this histopathologic sub
classification may not be clinically significant.4

Light microscopy shows a tumour of small, round blue
cells that lacks markers for lymphoma, neuroblastoma and
rhabdomyosarcoma. Cytogenetically 90% to 95% of the
Ewing's family of tumours have a translocation between the
EWS gene on chromosome 22 and the FLI1 gene on
chromosome 11 [t (11:22) (q24:q12)] or the ERG gene on
chromosome 21 [t (21; 22) (q22; q12)].5

Approximately 20% of patients present with metastatic
disease, of metastatic patients, 44% present with lung metastases
only and 51% have bone or bone marrow involvement (with or
without lung metastases) and 5% present with metastases in
other organs.3 Effective local and systemic therapies are
necessary for the cure of Ewing's sarcoma. Most chemotherapy
regimens are a combination of cyclophosphamide, doxorubicin
(Adriamycin), vincristine dactinomycin, ifosphamide and
etoposide. Both surgery and radiation therapy are effective local
therapy for the primary lesion.6-8
Ewing's sarcoma/primitive neuroectodermal tumour
of kidney is a rare and aggressive tumour, only few cases are
reported in the literature. It has a rapid clinical progression
with early metastases and death.2 Jimenez et al published
clinicopathologic and immunohistochemical analysis of 11
cases of Primary Ewing's sarcoma/PNET of the kidney and
mentioned a mean age of 18-49 years and mean follow up of
28 months (range 6-64 months) which showed 4 lung and
pleural metastases, 1 bone metastases, liver metastases, 2
local recurrences and 5 deaths from disease (median time to
death 16.8 months).9 In the case we are presenting the overall
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survival was 26 months with distant relapse free survival was
21 months, and the history of our case is almost similar to this
analysis and represent a typical ES/PNET of kidney affecting
a young female patient.

Since 1991, bone and soft tissue Ewing's tumour have
been treated similarly. The 5 year overall survival rate of patient
is more than 40% with localized disease at diagnosis. The
prognosis of patients with metastatic disease at diagnosis is
poor. In a report from the EICSS, the 5-year relapse free
survival for patients with lung metastases only was 29%. In
patients with metastatic disease at diagnosis, less than 50% of
all Ewing's sarcoma patients survive and it has been difficult to
show a significant improvement over the last 20 years.
Presently dose intensification by decreasing the interval
between cycles is being studied, using VACA/ifosphamideetoposide chemotherapy. With regards to local therapy the focus
should be on improving function and decreasing the incidence
of long term sequelae. It is unlikely that refinements in local
therapy with radiotherapy or surgery will significantly improve
the cure rate. Metastases remain the primary mechanism of
failure, and major improvements in the long term survival rates
will probably not occur until the development of better systemic
agents or genetic therapy targeted at the unique translocation
that produce these malignancies.10,11
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